- BioVaxys Technology Corp. (BIOV) has expanded its cancer vaccine platform with BVX-0922
- BioVaxys plans to advance an Investigator-Sponsored Clinical Trial Application (CTA) in the EU with the European Medicines Agency (EMEA) this year
- Co-founder and Chief Medical Officer Dr. David Berd sat down with Dave Jackson to discuss the news
- BioVaxys Technology is a clinical-stage biotechnology company that is developing viral and oncology vaccine platforms
- BioVaxys Technology Corp. (BIOV) opened trading at C$0.15 per share.
BioVaxys Technology Corp. (BIOV) has expanded its cancer vaccine platform with BVX-0922, its autologous haptenized tumor vaccine for colorectal cancer.
BioVaxys plans to advance an Investigator-Sponsored Clinical Trial Application (CTA) in the EU with the European Medicines Agency (EMEA) this year for BVX-0922. An Investigator Sponsored CTA is submitted to regulatory authorities by a clinical investigator who both initiates and conducts an initial clinical study of a new drug or procedure, and under whose immediate direction the investigational drug is administered.
Co-founder and Chief Medical Officer Dr. David Berd sat down with Dave Jackson to discuss the news.
BioVaxys Technology is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.
BioVaxys Technology Corp. (BIOV) opened trading at C$0.15 per share.
